231. Alpha-1-antitrypsin deficiency Clinical trials / Disease details
Clinical trials : 93 / Drugs : 77 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 36
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03945292 (ClinicalTrials.gov) | August 7, 2019 | 8/5/2019 | Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) | A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA] | Alpha 1-Antitrypsin Deficiency | Drug: Fazisiran Injection;Other: Placebo | Arrowhead Pharmaceuticals | NULL | Active, not recruiting | 18 Years | 75 Years | All | 40 | Phase 2 | United States;Germany;Italy;Netherlands;Portugal;Spain;Canada;Ireland;Sweden |